Drug-induced liver injury (DILI) is a drug-induced disease that not only complicates the treatment of the primary disease but may also lead to acute liver failure or even death in severe cases. Drugs commonly used in primary care, such as anti-infective agents and nonsteroidal anti-inflammatory drugs, are major causes of DILI. In addition, a large elderly population, comorbidities, and combination therapy with multiple drugs increase the risk of DILI in primary care. Therefore, primary care providers should proactively screen and monitor high-risk patients to identify potential DILI timely. Currently, diagnosis of DILI relies on the exclusion of liver diseases of other etiologies. Collection of detailed medical history of the patients and careful exclusion of other potential liver injury of other etiologies are crucial for accurate diagnosis. This guideline, developed based on evidence-based medicine from the latest research, aimed to provide primary care providers with professional guidance on the timely identification of suspected DILI cases and standardized diagnosis and management in clinical practice.
基金:
the National Key R & D Program of China (no. 2022YFC3502101) and the National Natural Science Foundation of China (nos. 82270619 and 82470621).
第一作者机构:[1]Shanghai Jiao Tong Univ, Shanghai Res Ctr Fatty Liver Dis, Sch Med, NHC Key Lab Digest Dis,Div Gastroenterol & Hepatol, Shanghai, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
Mao Yi Min,Tang Jie Ting,Lu Zhong Hua,et al.Chinese Guideline for the Diagnosis and Management of Drug-Induced Liver Injury in Primary Care (2024)[J].JOURNAL OF DIGESTIVE DISEASES.2025,doi:10.1111/1751-2980.13337.
APA:
Mao, Yi Min,Tang, Jie Ting,Lu, Zhong Hua,Shao, Ming,Zhao, Wei Feng...&Li, Xiao Yun.(2025).Chinese Guideline for the Diagnosis and Management of Drug-Induced Liver Injury in Primary Care (2024).JOURNAL OF DIGESTIVE DISEASES,,
MLA:
Mao, Yi Min,et al."Chinese Guideline for the Diagnosis and Management of Drug-Induced Liver Injury in Primary Care (2024)".JOURNAL OF DIGESTIVE DISEASES .(2025)